They say patience is a virtue. Working together with industry leading hospitals & universities to aid in our submission process has been invaluable.

Making sure all items are in order for a successful U.S. FDA IDE application is mission critical for us.

$RDGL #Cancer #biotech

As a public listed corporation OTC Markets Group (OTCQB:RDGL), we readily use K’s & Q’s to disseminate our financial information.

We utilize Social Media to highlight ‘key’ talking points when actively discussing our operations and our brands RadioGel™ & #isopet

Thank you.

$RDGL.

Taking a moment to remember those brave individuals this #MemorialDay . True #Heroes .

Good morning. We're pleased to share CEO Mike Korenko's detailed update of our May 20, 2022 meeting with the U.S. FDA. The update is available on our RadioGel™ website at: bit.ly/3sSy85i

#cancer #cancer treatment #Cancers #PRnT #RadioGel
#breakthrough #biotech $RDGL

Vivos Inc. may be who we are. This is what we do.

#extendinglives #cancertreatment #CancerResearch
#savinglives $RDGL

2). If this happens, we would submit the test plan to them for their review as part of another Pre-Submission dialog session. We've already outlined the new plan in anticipation of their recommendation and to move rapidly forward.

#Cancer #breakthrough #humans $RDGL

1). With our upcoming meeting on the 20th, early indications are that the U.S. FDA is satisfied with our health physics dosimetry calculations; but may request an additional animal test that proves once again that the Y-90 stays at the injection site captured by the hydrogel.

While the #Cancer consortium is actively discussing the #Cancer Moonshot initiative; #RadioGel ™ was just a concept a short decade ago, and definitely a Moon Shot. Through #IsoPet ®, we've shown the future is now, and #human patients are waiting.

youtu.be/QzSDs_7hzBk $RDGL

“We are continually striving to enhance and grow our Intellectual property portfolio to build value to our stakeholders and to strengthen our position as an emerging leader in precision radionuclide therapy.”

– Dr. Mike Korenko CEO • President

bit.ly/3Mc53td $RDGL

Vivos Inc. Provides Intellectual Property Protection Update globenewswire.com/news-release/2…

Happy Mother's Day.

'A mother is she who can take the place of all others, but whose place no one else can take.'

– Cardinal Mermillod #HappyMothersDay

The RadioGel™ team continues to reach to define what was once considered impossible. Our list of animals that had their lives extended is growing daily. In addition a huge stress relief for the pet parents. Pet lives matter.

Continually working toward #human #Cancer .

$RDGL

As you know we love our #pets 😀. This is an excellent program for those going through #Cancer treatment.

Please spread the awareness and tweet away.

Vivos Inc. is developing #precision #radiotherapy through RadioGel™. It may eventually be utilized in non-cancer applications; such as treating infections imbedded in bones that currently lead to amputation, which may occur in #diabetic patients.

#cancer #diabetes $RDGL

#InTheClinic

~Accelus announces 1st procedure integrating #Remi #Robotic System, & other #spinesurgery #tech

~Vivos Inc. implements multiple patient #IsoPet ® therapy day

~Golden Valley Memorial Healthcare is first to deploy MEDITECH’s solution, #ExpanseGenomics

Informative article. However, with our patented RadioGel™ device technology; we have a safe 'New Tool' with no tricks. It just works.

Old tool, new tricks cen.acs.org/pharmaceutical… via C&EN (Chemical & Engineering News)